Publications by authors named "Calum Cook"

Claim this Profile
I
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Kurt G Pike, Thomas A Hunt, Bernard Barlaam, David Benstead, Elaine Cadogan, Calum R Cook

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.
Frederick W Goldberg, Jason G Kettle, Gillian M Lamont, David Buttar, Attilla K T Ting, Calum R Cook

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of a Nitromethane-Carbonylation Strategy during Route Design of an Atropisomeric KRAS Inhibitor.
James J Douglas, Matthew R Tatton, Daniël de Bruin, David Buttar, Calum Cook

J Org Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Bernard Barlaam, Robert Casella, Justin Cidado, Calum Cook, Chris De Savi

J Med Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Richard A Ward, Mark J Anderton, Paul Bethel, Jason Breed, Calum Cook

J Med Chem· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.
Richard A Ward, Paul Bethel, Calum Cook, Emma Davies, Judit E Debreczeni

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
James J Crawford, Peter W Kenny, Jonathan Bowyer, Calum R Cook, Jonathan E Finlayson

J Med Chem· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.
Alexander G Dossetter, Jonathan Bowyer, Calum R Cook, James J Crawford, Jonathan E Finlayson

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Alexander G Dossetter, Howard Beeley, Jonathan Bowyer, Calum R Cook, James J Crawford

J Med Chem· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.
Chris De Savi, Andrew Pape, John G Cumming, Attilla Ting, Peter D Smith, Calum Cook

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis